{{Rsnum
|rsid=10499559
|Chromosome=7
|position=22069841
|Orientation=minus
|GMAF=0.1703
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 71.7 | 25.7 | 2.7
| HCB | 37.2 | 48.2 | 14.6
| JPT | 48.2 | 37.5 | 14.3
| YRI | 84.4 | 15.6 | 0.0
| ASW | 86.0 | 14.0 | 0.0
| CHB | 37.2 | 48.2 | 14.6
| CHD | 36.7 | 45.9 | 17.4
| GIH | 79.2 | 17.8 | 3.0
| LWK | 90.9 | 9.1 | 0.0
| MEX | 89.7 | 10.3 | 0.0
| MKK | 89.7 | 10.3 | 0.0
| TSI | 69.6 | 26.5 | 3.9
| HapMapRevision=28
}}

{{GWAS Summary
|SNP=rs10499559
|PubMedID=17903292
|Condition=Thyroid stimulating hormone
|Gene=RAPGEF5
|Risk Allele=
|pValue=8.00E-006
|OR=NA
|95CI=
|OA=1
}}

{{PharmGKB
|RSID=rs10499559
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:17903292; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS results: A genome-wide association for kidney function and endocrine-related traits in the NHLBI's Framingham Heart Study (Initial Sample Size: 810-1,010 individuals depending on measure (Framingham); Replication Sample Size: NR). This variant is associated with Thyroid stimulating hormone level.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA162356364
}}

{{GET Evidence
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs10499559
|overall_frequency_n=21
|overall_frequency_d=128
|overall_frequency=0.164062
|n_genomes=15
|n_genomes_annotated=0
|n_haplomes=17
|n_articles=0
|n_articles_annotated=0
|in_gwas=Y
|in_pharmgkb=Y
|autoscore=2
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}